Eph A2 expression is a predictive biomarker of poorer activity and efficacy of FOLFIRI + cetuximab in RAS WT metastatic colorectal cancer (mCRC) patients (pts) in the CAPRI GOIM trial

Authors :: Vincenzo Sforza
P. Vitale
Davide Ciardiello
Mariel C. Paul
N. Zanaletti
Paola Vitiello
Anna Maria Rachiglio
Giulia Martini
D. Rizzi
Nicola Normanno
Evaristo Maiello
Fortunato Ciardiello
Erika Martinelli
Teresa Troiani
Claudia Cardone
Veronica Moreno-Viedma
Maria Sibilia
Salvatore Napolitano
Source :: Annals of Oncology. 28:v576
Publication Year :: 2017
Publisher :: Elsevier BV, 2017.

Subjects :: Oncology
medicine.medical_specialty
Cetuximab
business.industry
Colorectal cancer
Hematology
medicine.disease
Internal medicine
FOLFIRI
Medicine
business
Predictive biomarker
medicine.drug

Full Text Access

Tools